The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2019 | Determining the prognostic significance of upfront radiation therapy in MM
Peter Barth
• 14 Sep 2019
Peter Barth, MD, of Brown University, Providence, RI, explains the rationale behind his research into the prognostic significance of upfront radiation therapy in multiple myeloma (MM). This was discussed at the International Myeloma Workshop (IMW) 2019, in Boston, MA.
